about
Extension of dynamic range of sensitive nanoparticle-based immunoassays.Four automated 25-OH total vitamin D immunoassays and commercial liquid chromatography tandem-mass spectrometry in Finnish population.Adding ADAM12 in risk calculation program does not improve the detection rate of trisomies 18 and 13 in first trimester screening.The secretion of PAPP-A, ADAM12, and PP13 correlates with the size of the placenta for the first month of pregnancy.More invasive procedures are done to detect each case of Down's syndrome in younger women.A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe. The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study.False-Negative Results in Routine Combined First-Trimester Screening for Down Syndrome in FinlandSerum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndromeFirst trimester biochemistry at different maternal agesFirst trimester Down syndrome screening is less effective and the number of invasive procedures is increased in women younger than 35 years of ageEvidence-based laboratory medicine: how well do laboratories follow recommendations and guidelines? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) studyFirst-trimester maternal serum ADAM12-s and PAPP-A levels are altered in pregnancies conceived after assisted reproduction techniques (ART)Extremely large nuchal translucency measurement predicts adverse pregnancy outcomeNovel sensitive cardiac troponin I immunoassay free from troponin I-specific autoantibody interferenceQuantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMQuantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM
P50
Q46030189-E674F28D-9768-4A9A-961E-DD6B6F0B77AEQ46534480-86A90E26-96D4-4218-BE05-1BAF9449DCEAQ46925141-DDB6BC46-EE58-4EDA-9143-35B484CB5E1BQ47348629-FEDEA473-B3E4-4EC4-A263-10B101188A0FQ51053067-31D78626-D7C2-4491-8C74-5F5AC1D3DDE0Q53781358-610BBBF7-A8F6-48CB-B082-50799BCCADB4Q61851870-8A653F7F-7834-4AFE-BB1A-AA185AB424A3Q77578776-06C1E301-7E4E-4CE3-85DC-F7C261BCF838Q82654804-F1BA7755-28C5-430E-B10C-B163988ED5B9Q83766162-B8D25BDE-BBEB-4731-9492-8D02F7DF4D51Q85002407-F0F0E026-E5ED-4951-8AED-B58834254358Q86962072-C056C80A-60CB-4822-8F3A-35573CE7A250Q87395767-6246F21E-CBCB-42B2-A937-097BC866710BQ87420855-5A11A143-9210-472F-903F-FE7C41ADF435Q92120131-05FA80C4-9C5B-4657-AFE9-EE6A46F16DF1Q92585003-BDF26CF1-D9BA-4721-96FD-A95BDC322D7B
P50
description
researcher
@en
wetenschapper
@nl
name
P Laitinen
@en
P Laitinen
@nl
type
label
P Laitinen
@en
P Laitinen
@nl
prefLabel
P Laitinen
@en
P Laitinen
@nl
P106
P31
P496
0000-0002-5455-3220